Haiyi Jiang

Publications by Year

Research Areas

Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, Peptidase Inhibition and Analysis, Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms

Most-Cited Works

• → Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma(2009)8,200 cited
• → Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer(2017)4,427 cited
• → Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial(2019)2,107 cited
• → Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)(2011)1,595 cited
• → Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial(2020)668 cited
• → Interstitial Lung Disease in Japanese Patients with Lung Cancer(2008)484 cited
• → Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial(2015)405 cited
• → Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer(2008)365 cited
• → Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN(2022)297 cited
• → Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer(2024)227 cited